- Posted Thursday August 25, 2016
stepNout Run/Walk/Dash seeks end to pancreatic cancer, soon the nation’s 3rd leading cause of cancer death
SCOTTSDALE, Ariz. - Aug. 25, 2016 - This year, pancreatic cancer is projected to eclipse breast cancer as the third leading cause of cancer-related death in the U.S.
The Translational Genomics Research Institute (TGen) is determined to reverse this trend in pancreatic cancer by enlisting the help of more than 1,000 participants at the 11th annual stepNout Run/Walk/Dash for pancreatic cancer research, Nov. 6 in Scottsdale.
Guest speaker at this year's stepNout is Scottsdale Mayor Jim Lane.
"We are incredibly grateful to the hundreds of volunteers who have truly accelerated the development of new treatments for pancreatic cancer," said Michael Bassoff, President of the TGen Foundation. "These generous runners and community leaders have brought hope and answers to pancreatic cancer patients around the world."
Be sure to put on your running shoes for stepNout, a family-friendly morning of races, music, games, and activities - including a photo booth and face painting - all celebrating TGen's efforts to stomp out pancreatic cancer.
Dr. Daniel Von Hoff, TGen Distinguished Professor and Physician-In-Chief, said more effective treatments for pancreatic cancer are needed. Pancreatic cancer this year will take the lives of nearly 42,000 Americans, a more than 10 percent increase in the past 5 years.
"The death rate for other leading cancers have been flat in recent years because of more effective treatments," said Dr. Von Hoff. "We are making progress in treating patients with improvement in average survival and for the first time having some very long term survivors. We need continued, dedicated funding to improve on these promising results to our studies and benefit pancreatic patients who need our help now."
Median survival for patients with advanced disease was less than 6 months, and the 5-year survival rate was less than 10 percent. But thanks to fundraising efforts like stepNout, these statistics are improving.
Under Dr. Von Hoff's leadership, and in collaboration with HonorHealth, TGen pioneered a major international clinical trial that led the FDA in 2013 approved the use of Abraxane in combination with gemcitabine, which now is the nation's standard of care for this disease. Two ongoing TGen-led studies are showing even greater promise, with tumor reductions of at least 30 percent in 3 in 4 patients, and the elimination of tumors in 1 in 5 patients.
Competitive and fun races at stepNout are geared for all ages and abilities, including the event's signature 5K run. Online registration ends Nov. 1, though participants can register at the event. This is the third year stepNout will be at the Scottsdale Sports Complex, northeast of Bell and Hayden roads.
The annual event has raised more than $1 million since it started in 2006. Nearly $135,000 was raised last year, and organizers are aiming for $150,000 this year on their way towards an overall goal of $2 million.
And you don't have to be at stepNout to help. You can donate at www.tgenfoundation.org/step.
If you go to stepNout:
What: TGen's 11th annual stepNout Run/Walk/Dash for pancreatic cancer research.
Where: Scottsdale Sports Complex, 8081 E. Princess Drive, northeast of Hayden and Bell roads, between Loop 101 and Frank Lloyd Wright Boulevard.
When: 7:30-11 a.m. Sunday, Nov. 6. Registration starts at 7:30 a.m.; a competitive 5K run begins at 9 a.m.; a fun 1-mile run/walk starts at 9:15 a.m.; a free 50-yard kids' dash is planned for 10:30 a.m.
Cost: Registration fees range from $10 to $30, depending on age. Costs increase by $5 after Oct. 21. Children ages 5 and under are free.
More information and registration: www.tgenfoundation.org/step and click on events. Contact Andrea Daly at (602) 343-8572 or by email at email@example.com.
# # #
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with neurological disorders, cancer, and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit: www.tgen.org. Follow TGen on Facebook, LinkedIn and Twitter @TGen.
TGen Senior Science Writer